These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11524711)

  • 1. Minimizing potential resistance: the molecular view.
    Courvalin P; Trieu-Cuot P
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S138-46. PubMed ID: 11524711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Quinolones and Streptococcus pneumoniae. Mechanisms of action and resistance].
    Taléns-Visconti R; Garrigues TM; Cantón E
    Rev Esp Quimioter; 2002 Dec; 15(4):313-24. PubMed ID: 12587036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antibiotic resistome: the nexus of chemical and genetic diversity.
    Wright GD
    Nat Rev Microbiol; 2007 Mar; 5(3):175-86. PubMed ID: 17277795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
    Etienne M; Croisier D; Charles PE; Lequeu C; Piroth L; Portier H; Drlica K; Chavanet P
    J Infect Dis; 2004 Oct; 190(8):1472-5. PubMed ID: 15378440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
    Schurek KN; Adam HJ; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2006 Sep; 28(3):266-9. PubMed ID: 16904294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States.
    Doern GV
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S187-92. PubMed ID: 11524718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence].
    Nseir S; Ader F; Marquette CH; Durocher A
    Pathol Biol (Paris); 2005; 53(8-9):470-5. PubMed ID: 16176863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotics and antibiotic resistance genes in natural environments.
    Martínez JL
    Science; 2008 Jul; 321(5887):365-7. PubMed ID: 18635792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease.
    Pérez-Trallero E; Marimón JM; González A; Ercibengoa M; Larruskain J
    Clin Infect Dis; 2005 Aug; 41(4):560-4. PubMed ID: 16028169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Tillotson GS; Zhao X; Drlica K
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102062
    [No Abstract]   [Full Text] [Related]  

  • 12. Will reduction of antibiotic use reduce antibiotic resistance?: The pneumococcus paradigm.
    Dagan R; Barkai G; Leibovitz E; Dreifuss E; Greenberg D
    Pediatr Infect Dis J; 2006 Oct; 25(10):981-6. PubMed ID: 17006311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM
    Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?
    Mandell LA; Peterson LR; Wise R; Hooper D; Low DE; Schaad UB; Klugman KP; Courvalin P
    Clin Infect Dis; 2002 Sep; 35(6):721-7. PubMed ID: 12203170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.
    Low DE
    Clin Infect Dis; 2004 May; 38 Suppl 4():S357-62. PubMed ID: 15127370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa.
    Zhanel GG; Hoban DJ; Schurek K; Karlowsky JA
    Int J Antimicrob Agents; 2004 Dec; 24(6):529-35. PubMed ID: 15555873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of S. pneumoniae to fluoroquinolines--US, 1995-1999.
    Ann Pharmacother; 2001 Nov; 35(11):1509. PubMed ID: 11724112
    [No Abstract]   [Full Text] [Related]  

  • 19. Minimizing potential resistance: the molecular view--a comment on Courvalin and Trieu-Cuot.
    Hooper DC
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S157-60. PubMed ID: 11524713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread use of fluoroquinolones versus emerging resistance in pneumococci.
    Goldstein EJ; Garabedian-Ruffalo SM
    Clin Infect Dis; 2002 Dec; 35(12):1505-11. PubMed ID: 12471570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.